Summary and Conclusions
The evaluation of patients with respiratory disease suspected or alleged to complicate exposure to asbestos requires the synthesis of clinical, radiographic, and laboratory data, as well as data gleaned from the inspection of pathologic specimens. The examination of cytologic materials including body cavity fluids, bronchial washings, and sputa (often obtained with a minimum of expense and attendant morbidity) may provide a wealth of information regarding the various disease states believed to be related to prior asbestos exposure. Moreover, these specimens may lend themselves to the application of special techniques discussed elsewhere in this book to identify and quantify asbestos fibers and thereby implicate them in the causation of disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Greenberg SD, Hurst GA, Matlage WT, Miller JM, Hurst IJ, Mabry LC: Tyler asbestos workers program. Ann NY Acad Sci 271:353–364, 1976.
Roggli VL, Greenberg SD, Seitzman LH, McGavran MH, Hurst GA, Spivey CG, Nelson KG, Hieger LR: Pulmonary fibrosis, carcinoma and asbestos body counts in amosite asbestos workers. Am J Clin Pathol 73:496–503, 1980.
Stewart MJ, Haddow AC: Demonstration of the peculiar bodies of pulmonary asbestosis in material obtained by lung puncture and in the sputum. J Pathol Bacteriol 32:172, 1929.
An SH, Koprowska I: Primary cytologic diagnosis of asbestosis associated with bronchogenic carcinoma: Case report and review of the literature. Acta Cytol 6:391–398, 1962.
Huuskonen MS, Taskinen E, Vaaranen V: Sputum cytology of asbestosis patients. Scand J Work Environ Health 4:284–294, 1978.
Gupta PK, Frost JK: Cytologic changes associated with asbestos exposure. Sem Oncol 8:283–289, 1981.
Kotin P, Paul W: Results of a lung cancer detection program in an asbestos industry. Recent Results in Cancer Research 82:131–137, 1982.
Dodson RF, Williams MG, McLarty JW, Hurst GA: Asbestos bodies and particulate matter in sputum from former asbestos workers: An ultrastructural study. Acta Cytol 27:635–40, 1983.
Kobusch AB, Simard A, Feldstein M, Vauclair R, Gibbs GW, Bergeron F, Morissette N, Davis R: Pulmonary cytology in chrysotile asbestos workers. J Chron Dis 37:599–607, 1984.
DeMay RM: Respiratory Cytology. Ch. 7 In: The Art and Science of Cytopathology: Exfoliative Cytology, Chicago: ASCPPress, 1996, pp. 207–256.
Bocking A, Biesterfeld S, Chatelain R: Diagnosis of bronchial carcinoma on sections of paraffin-embedded sputum: Sensitivity and specificity of an alternative to routine cytology. Acta Cytol 36:37–42, 1992.
Nakajima J, Manabe T, Yagi S: Appearance of mesothelioma cells in sputum: A case report. Acta Cytol 36:731–736, 1999.
Naryshkin S, Young NA: Respiratory cytology: A review of non-neoplastic mimics of malignancy. Diag Cytopathol 9:89–97, 1993.
Colby TV, Koss MN, Travis WT: Tumors of the Lower Respiratory Tract. Atlas of Tumor Pathology, Series 3, Fascicle 13, Washington, DC: Armed Forces Institute of Pathology, 1995, pp. 259–278.
Epler GR, McLoud TC, Gaensler EA: Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 247:617–622, 1982.
Chahinian AP, Pajak TF, Holand JF: Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 96:746–775, 1982.
Whitaker D, Shilkin KB, Sterrett GF: Cytologic appearance of malignant mesothelioma, In: Malignant Mesothelioma (Henderson DW, Shilkin KB, Langlois SLP, eds.) New York: Hemisphere, 1991, pp. 167–182.
Leong ASY, Stevens MW, Mukherjee TM: Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical and ultrastructural correlation. Sem Diag Pathol 9:141–150, 1992.
Stevens MW: Cytopathology of malignant mesothelioma: A stepwise logistic regression analysis. Diag Cytopathol 8:333–344, 1992.
Zakowski MF, Ianuale-Sherman A: Cytology of pericardial effusions in AIDS patients. Diag Cytopathol 9:266–269, 1993.
McCaughey WTE, Kannerstein M, Churg J: Tumors and pseudotumors of the serous membranes. In: Atlas of Tumor Pathology, Series 2, Fascicle 20, Washington, DC: Armed Forces Institute of Pathology, 1985, pp. 60–61.
Attanoos RL, Gibbs AR: Pathology of malignant mesothelioma. Histopathol 30:403–418, 1997.
Tickman RJ, Cohen CC, Varma VA, Fekete PS, Derose PB: Distinction between carcinoma cells and mesothelial cells in serous effusions—usefulness of immunohistochemistry. Acta Cytol 34:491–496, 1990.
Fetsch PA, Simsir A, Abati A: Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diag Cytopathol 25:158–161, 2001.
Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J: Immunocyto-chemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 93:68–72, 2001.
Barberis MC, Faleri M, Veronese S, Casadio C, Viale G: Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Diag Cytopathol 41:1757–1761, 1997.
Hecht JL, Pinkus JL, Weinstein LJ, Pinkus GS: The value of thyroid transcription factor 1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 116:483–488, 2001.
Motherby H, Kube M, Friedrichs N, Jadjari B, et al.: Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology. Part 1. Analyt Cell Pathol 19:7–20, 1999.
Wieczorek TJ, Krane JF: Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 90:312–319, 2000.
Kitazume H, Kitamura K, Mukai K, Inayama Y, Kawano N, Nakamura N, Sano J, Mitsui K, Yoshida S, Nakatani Y: Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 90:55–60, 2000.
Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg R, Johansen P: The role of desmin and N-cadherin in effusion cytology: A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405–1412, 2001.
Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A: E-cadherin, N-cadherin and calretinin in pleural effusions: the good, the bad, the worthless. Diag Cytopathol 20:125–130, 1999.
Lee A, Baloch ZW, Yu G, Gupta PK: Mesothelial hyperplasia with reactive atypia: diagnostic pitfalls and role of immunohistochemical studies—a case report. Diag Cytopathol 22:113–116, 2000.
Sakuma N, Toshiaki K, Ishihara T: Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells. Acta Cytol 43:777–779, 1999.
DiBonito L, Falconieri G, Colautti I, Gori DB, Dudine S, Giarelli L: Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diag Cytopathol 9:25–31, 1992.
Sherman ME, Mark EJ: Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med 114:845–851, 1990.
Johnston WW: Cytologic correlations. Ch. 31 In: Pulmonary Pathology (Dail DH, Hammar SP, eds.) New York: Springer-Verlag, 1988, pp. 1029–1095.
Yu GH, Baloch ZW, Gupta PK: Cytopathology of metastatic mesothelioma in fine needle aspiration specimens. Diag Cytopathol 20:328–332, 1999.
Nguyen GK, Akin MR, Villanueva RR, Slatnik J: Cytopathlogy of malignant mesothelioma of the pleura in fine needle aspiration biopsy. Diag Cytopathol 21:253–259, 1999.
Yu GH, Soma L, Hahn S, Friedberg JS: Changing clinical course of patients with malignant mesothelioma: implications for FNA cytology and utility of immunocytochemical staining. Diag Cytopathol 24:322–327, 2001.
Obers VJ, Leiman G, Girdwood RW, Spiro FI: Primary malignant pleural tumors (mesotheliomas) presenting as localized masses: Fine needle aspiration cytologic findings, clinical and radiologic features and review of the literature. Acta Cytol 32:567–575, 1988.
Sterrett GF, Whitaker D, Shilkin KB, Walters MNI: Fine needle aspiration cytology of malignant mesothelioma. Acta Cytol 31:185–193, 1987.
Friedman MT, Gentile P, Tarectecan A, Fuchs A: Malignant mesothelioma: Immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Arch Pathol Lab Med 120:959–966, 1996.
Granados R, Cibas ES, Fletcher JA: Cytogenetic analysis from effusions malignant mesothelioma—a diagnostic adjunct to cytology. Acta Cytol 38:711–717, 1994.
Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES: The role of cytologic evaluation of pleural fluid in the diagnosis of mesothelioma. Chest 111:106–109, 1997.
Greenberg SD: Asbestos lung disease. Sem Resp Med 4:130–136, 1982.
Mace ML, McLemore TL, Roggli VL, Brinkley BR, Greenberg SD: Scanning electron microscopic examination of human asbestos bodies. Cancer Lett 9:95–104, 1980.
McLemore TL, Mace ML, Roggli VL, Marshall MV, Lawrence EC, Wilson RK, Martin RR, Brinkley BR, Greenberg SD: Asbestos body phagocytosis by human free alveolar macrophages. Cancer Lett 9:85–93, 1980.
Dumortier P, Broucke I, De Vuyst P: Pseudoasbestos bodies and fibers in bronchoalveolar lavage of refractory ceramic fiber users. Am J Respir Crit Care Med 164:499–503, 2001.
Roggli VL, Piantadosi CA, Bell DY: Asbestos bodies in bronchoalveolar lavage fluid: A study of 20 asbestos-exposed individuals and comparison to patients with other chronic interstitial lung diseases. Acta Cytol 30: 470–476, 1986.
Modin BE, Greenberg SD, Buffler PA, Lockhart JA, Seitzman LH, Awe RJ: Asbestos bodies in a general hospital/clinic population. Acta Cytol 26: 667–670, 1982.
Farley ML, Greenberg SD, Shuford EH, Hurst GA, Spivey CG: Ferruginous bodies in sputa of former asbestos workers. Acta Cytol 21:693–700, 1977.
Bignon J, Sebastien P, Jaurand MC, Hem B: Microfiltration methods for quantitative study of fibrous particles in biologic specimens. Environ Health Persp 9:155–160, 1974.
Roggli VL, McLarty JW, Greenberg SD, Hurst GA, Hieger LR, Farley ML, Mabry LC: Comparison of sputum and lung asbestos body counts in former asbestos workers. Am Rev Respir Dis 122:941–945, 1980.
McLarty JW, Greenberg SD, Hurst GA, Spivey CG, Seitzman LH, Hieger LR, Farley ML, Mabry LC: The clinical significance of ferruginous bodies in sputa. J Occup Med 22:92–96, 1980.
Teschler H, Konietzko N, Schoenfeld B, Ramin C, Schraps T, Costabel U: Distribution of asbestos bodies in the human lung as determined by bronchoalveolar lavage. Am Rev Respir Dis 147:1211–1215, 1993.
De Vuyst P, Dumortier P, Moulin E, Yourassowsky N, Yernault JC: Diagnostic value of asbestos bodies in bronchoalveolar lavage fluid. Am Rev Respir Dis 136:1219–1224, 1987.
Roggli VL, Coin PG, McIntyre NR, Bell DY: Asbestos content of bronchoalveolar lavage fluid: a comparison of light and scanning electron microscopic analysis. Acta Cytol 38:502–510, 1994.
Karjalainen A, Anttila A, Mantyla T, Taskinen E, Kyyronen P, Tukianen P: Asbestos bodies in bronchoalveolar lavage fluid in relation to occupational history. Am J Ind Med 26:645–654, 1994.
Karjalainen A, Piipari R, Mantyla T, Monkkonen M, Numinen M, Tukianen P, Vanhala E, Anttila S: Asbestos bodies in bronchoalveolar lavage in relation to asbestos bodies and asbestos fibers in lung parenchyma. Eur Respir J 9:1000–1005, 1996.
De Vuyst P, Dumortier P, Moulin E: Asbestos bodies in bronchoalveolar lavage reflects lung asbestos body concentration. Eur Resp J 1:362–367, 1988.
Sebastien P, Armstrong B, Monchaux G, Bignon J: Asbestos bodies in bronchoalveolar lavage fluid and in lung parenchyma. Am Rev Respir Dis 137:75–78, 1988.
Schwartz DA, Galvin JR, Burmeister LF, Merchant RK, Dayton CS, Merchant JA, Hunninghake GW: The clinical utility and reliability of asbestos bodies in bronchoalveolar fluid. Am Rev Respir Dis 144:684–688, 1991.
Albin M, Johansson L, Pooley FD, Jakobsson K, Attewell R, Mitra R: Mineral fibres, fibrosis and asbestos bodies in lung tissue. Br J Ind Med 47:767–774, 1990.
Teschler H, Hoheisel G, Fischer M, Muller KM, Konietzko N, Costabel U: The content of asbestos bodies in the bronchoalveolar fluid as a parameter of an increased pulmonary asbestos load. Deutsch Med Wochenschr 118:1749–1754, 1993.
Teschler H, Friedrichs KH, Hoheisel GB, Wick G, Soltner U, Thompson AB, Konietzko N, Costabel U: Asbestos fibers in bronchoalveolar lavage and lung tissue of former asbestos workers. Am J Respir Crit Care Med 149:641–645, 1994.
Dumortier P, Coplu L, de Martier V, Emri S, Baris I, De Vuyst P: Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. Am J Respir Crit Care Med 158:1815–1824, 1998.
De Vuyst P, Dumortier P, Gevenois PA: Analysis of asbestos bodies in BAL from subjects with particulate exposures. Am J Ind Med 31:699–704, 1997.
Roggli VL, Johnston WW, Kaminsky DB: Asbestos bodies in fine needle aspirates of the lung. Acta Cytol 28:494–498, 1984.
Leiman G: Asbestos bodies in fine needle aspirates of lung masses. Acta Cytol 35:171–174, 1991.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Sporn, T.A., Butnor, K.J., Roggli, V.L. (2004). Cytopathology of Asbestos-Associated Diseases. In: Roggli, V.L., Sporn, T.A., Oury, T.D. (eds) Pathology of Asbestos-Associated Diseases. Springer, New York, NY. https://doi.org/10.1007/0-387-21819-X_9
Download citation
DOI: https://doi.org/10.1007/0-387-21819-X_9
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20090-3
Online ISBN: 978-0-387-21819-9
eBook Packages: Springer Book Archive